SPECIAL NOTICE
A -- Office of Biomedical Advanced Research and Development Authority Broad Agency Announcement (BAA)
- Notice Date
- 11/21/2023 11:23:42 AM
- Notice Type
- Special Notice
- NAICS
- 541715
— Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Contracting Office
- ASPR OFFICE OF THE ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE Washington DC 20201 USA
- ZIP Code
- 20201
- Response Due
- 9/29/2023 1:03:00 PM
- Archive Date
- 10/14/2023
- Point of Contact
- Deitra Williams, Corneilus Stephens
- E-Mail Address
-
Deitra.Williams@hhs.gov, Corneilus.Stephens@hhs.gov
(Deitra.Williams@hhs.gov, Corneilus.Stephens@hhs.gov)
- Description
- The overall objective of this contract is to develop multiplexed SARS-CoV-2 antigen panel assay kits for�human antibody (e.g., IgA and IgG when appropriate) quantification by electrochemiluminescence in�serum and mucosal samples. The antigen panel assay kits shall be capable of measuring total�antibodies that block binding of angiotensin-converting enzyme 2 (ACE2) to the receptor binding�domain (RBD) of the SARS-CoV-2 ancestor and selected variants printed in custom configurations. The�antigen panels shall be capable of measuring Ig, IgG and IgA antibodies that bind to the whole Spike�(S), receptor binding domain (RBD) and nucleocapsid (N) antigens of the SARS-CoV-2 ancestor and�selected variants printed in custom configurations. The antigen panel assay kits shall include�appropriate standards and controls to support development and validation of the assays described above at USG-designated laboratories. The scope of work includes providing multiplexed SARS-CoV-2 antigen panels assay kits for human�antibody (e.g., IgA and IgG as appropriate), to be used in either direct SARS-CoV-2 antigen-binding or�ACE2 receptor-blocking, quantification by electrochemiluminescence. The Contractor will function as a�USG antigen panel assay kit development and ISO 9001 manufacturer to support advanced research�and development and evaluation of COVID-19 vaccines. Data from these panels may be used in�primary, secondary, and exploratory immunogenicity endpoint analyses for vaccine clinical studies as well as monitoring their subsequent efficacy.
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/10ec0499515b46859292123d8325a1dd/view)
- Place of Performance
- Address: Rockville, MD, USA
- Country: USA
- Country: USA
- Record
- SN06891223-F 20231123/231121230045 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |